Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Obinutuzumab in Rituximab Refractory or Intolerant Immune-Mediated Thrombotic Thrombocytopenic Purpura

Julia Weisinger, Jehane Fadlallah, Christelle Barbet, Francois Provot, Pascale Poullin, Antoine Neel, Manon Marie, Virginie Rieu, Tarik Kanouni, Olivier Moranne, Elie Azoulay, Bérangère Joly, Agnès Veyradier, Paul Coppo

Blood (2024) 144 (Supplement 1): 139.

https://doi.org/10.1182/blood-2024-204726

Published: 2024

Journal Articles

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study

Blood (2021) 137 (18): 2438–2449.

https://doi.org/10.1182/blood.2020009280

Published: 2021

Includes: Supplemental data

Journal Articles

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Blood (2021) 137 (6): 733–742.

https://doi.org/10.1182/blood.2020008021

Published: 2021

Includes: Supplemental data

Journal Articles

Patients with refractory catastrophic antiphospholipid syndrome respond inconsistently to eculizumab

Cécile M. Yelnik, Sébastien Miranda, Arsène Mékinian, Estibaliz Lazaro, Thomas Quéméneur, François Provot, Marie Frimat, Sandrine Morell-Dubois, Véronique Le Guern, Eric Hachulla, Nathalie Costedoat-Chalumeau, Marc Lambert

Blood (2020) 136 (21): 2473–2477.

https://doi.org/10.1182/blood.2020007499

Published: 2020

Journal Articles

Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group

Blood (2020) 136 (19): 2103–2117.

https://doi.org/10.1182/blood.2020005221

Published: 2020

Includes: Supplemental data

Journal Articles

Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival

Blood (2019) 134 (24): 2209–2217.

https://doi.org/10.1182/blood.2019000748

Published: 2019

Includes: Supplemental data

Journal Articles

Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study

Florent Joly, Camille Cohen, Vincent Javaugue, Sébastien Bender, Mohamed Belmouaz, Bertrand Arnulf, Bertrand Knebelmann, Mathilde Nouvier, Vincent Audard, François Provot, Viviane Gnemmi, Dominique Nochy, Jean Michel Goujon, Arnaud Jaccard, Guy Touchard, Jean Paul Fermand, Christophe Sirac, Frank Bridoux

Blood (2019) 133 (6): 576–587.

https://doi.org/10.1182/blood-2018-09-872028

Published: 2019

Includes: Supplemental data

Journal Articles

Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura

Blood (2018) 132 (20): 2143–2153.

https://doi.org/10.1182/blood-2018-04-840090

Published: 2018

Includes: Supplemental data

Journal Articles

Efficacy of Eculizumab in Gemcitabine-Induced Thrombotic Microangiopathy: Experience of the French Thrombotic Microangiopathies Reference Centre

Maximilien Grall, MD, Francois Provôt, MD, Jean-Philippe Coindre, MD, Claire Pouteil-Noble, MD PhD, Dominique Guerrot, MD PhD, Ygal Benhamou, MD, Dominique Bordessoule, MD PhD, Agnes Veyradier, MD PhD, Paul Coppo, MD PhD, Steven Grange, MD

Blood (2016) 128 (22): 136.

https://doi.org/10.1182/blood.V128.22.136.136

Published: 2016

Journal Articles

Eculizumab Prevents Thrombotic Microangiopathy: Long-Term Follow-up Study of Patients with Atypical Hemolytic Uremic Syndrome

Laurence A. Greenbaum, MDPhD, Yahsou Delmas, MD PhD, Fadi Fakhouri, MD PhD, John F. Kincaid, MD MA, Christoph Licht, MD FRCP(C), FASN, Enrico E. Minetti, MD, Chris Mix, MD, Francois Provôt, MD, Eric Rondeau, MD PhD, Neil Sheerin, BSc, MBBS, MRCP, PhD FRCP, Jimmy Wang, PhD, Laurent E. Weekers, MD, Jan Menne, MD

Blood (2015) 126 (23): 2252.

https://doi.org/10.1182/blood.V126.23.2252.2252

Published: 2015

Journal Articles

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura

Miguel Hie, Julie Gay, Lionel Galicier, François Provôt, Claire Presne, Pascale Poullin, Guy Bonmarchand, Alain Wynckel, Ygal Benhamou, Philippe Vanhille, Aude Servais, Dominique Bordessoule, Jean-Philippe Coindre, Mohamed Hamidou, Jean-Paul Vernant, Agnès Veyradier, Paul Coppo, the French Thrombotic Microangiopathies Reference Centre

Blood (2014) 124 (2): 204–210.

https://doi.org/10.1182/blood-2014-01-550244

Published: 2014

Includes: Supplemental data

Journal Articles

Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Adult Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS)

Fadi Fakhouri, Maryvonne Hourmant, MD, Spero R. Cataland, M.D., Mario Espinosa, A. Osama Gaber, Jan Menne, Enrico Minetti, Francois Provot, Eric Rondeau, Piero Ruggenenti, Laurent Weekers, Masayo Ogawa, MD, FAAP, Camille L. Bedrosian, MD, Christophe Legendre

Blood (2013) 122 (21): 2179.

https://doi.org/10.1182/blood.V122.21.2179.2179

Published: 2013

Journal Articles

Preemptive Rituximab Infusions Efficiently Prevent Relapses In Acquired Thrombotic Thrombocytopenic Purpura. Experience Of The French Thrombotic Microangiopathies Reference Center

Miguel HIE, MD, Julie Gay, MD, Lionel Galicier, MD, Francois Provot, Sandrine Malot, Pascale Poullin, MD, Guy Bonmarchand, MD, Alain Wynckel, MD, Ygal Benhamou, MD, Philippe Vanhille, Dominique Bordessoule, MD, PhD, Jean-Paul Vernant, Agnes Veyradier, MD PhD, Paul Coppo, MD PhD

Blood (2013) 122 (21): 448.

https://doi.org/10.1182/blood.V122.21.448.448

Published: 2013

Journal Articles

A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function

Lubka T. Roumenina, Marie Frimat, Elizabeth C. Miller, Francois Provot, Marie-Agnes Dragon-Durey, Pauline Bordereau, Sylvain Bigot, Christophe Hue, Simon C. Satchell, Peter W. Mathieson, Christiane Mousson, Christian Noel, Catherine Sautes-Fridman, Lise Halbwachs-Mecarelli, John P. Atkinson, Arnaud Lionet, Veronique Fremeaux-Bacchi

Blood (2012) 119 (18): 4182–4191.

https://doi.org/10.1182/blood-2011-10-383281

Published: 2012

NARROW

Obinutuzumab in Rituximab Refractory or Intolerant Immune-Mediated Thrombotic Thrombocytopenic Purpura

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

Patients with refractory catastrophic antiphospholipid syndrome respond inconsistently to eculizumab

Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group

Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival

Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study

Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura

Efficacy of Eculizumab in Gemcitabine-Induced Thrombotic Microangiopathy: Experience of the French Thrombotic Microangiopathies Reference Centre

Eculizumab Prevents Thrombotic Microangiopathy: Long-Term Follow-up Study of Patients with Atypical Hemolytic Uremic Syndrome

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura

Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Adult Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS)

Preemptive Rituximab Infusions Efficiently Prevent Relapses In Acquired Thrombotic Thrombocytopenic Purpura. Experience Of The French Thrombotic Microangiopathies Reference Center

A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only